후천성 희귀 혈액 질환 치료제 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 치료법, 질환 지표, 유통 채널, 지역별 및 경쟁(2021-2031년)

The global market for therapeutics targeting acquired orphan blood diseases is projected to expand significantly, from USD 8.13 billion in 2025 to USD 12.82 billion by 2031, demonstrating a compound annual growth rate of 7.89%. This market encompasses specialized pharmaceutical agents like immunosuppressants, coagulation factors, and biologics, specifically developed for rare non-congenital hematologic conditions such as acquired hemophilia A and paroxysmal nocturnal hemoglobinuria. Key drivers for this growth include advancements in diagnostic technologies that improve patient identification and robust regulatory support, exemplified by orphan drug designations, which reduce commercial risks associated with developing treatments for small patient groups. Furthermore, the introduction of targeted therapies that address specific autoimmune mechanisms is crucial for ongoing sector development, as these offer superior clinical outcomes compared to conventional non-specific treatments.

Despite its growth potential, the market faces a considerable challenge due to the high costs of drug development and the resultant elevated pricing, which often meets resistance from reimbursement entities and insurance providers. This financial strain limits patient access and creates substantial barriers to commercial adoption, particularly within healthcare systems sensitive to costs. The niche character of this market is highlighted by the 'American Society of Hematology's 2024 estimate that acquired hemophilia A has an annual incidence of approximately 1.5 cases per million population. Such low patient numbers necessitate higher pricing to maintain profitability, thereby exacerbating difficulties in achieving consistent market reimbursement.

Market Driver

The global market for acquired orphan blood diseases therapeutics is being significantly transformed by advancements in novel biologics and targeted therapies, which are steadily replacing broad-spectrum immunosuppressants with treatments that act on specific mechanisms. The introduction of precision medicines, including proximal complement inhibitors, has notably enhanced the management of conditions like paroxysmal nocturnal hemoglobinuria (PNH) and cold agglutinin disease (CAD), leading to swift commercial adoption. For example, Ultomiris generated nearly $1.1 billion in revenue in Q4 2024, a 33% increase, as reported by BioSpace in February 2025. Similarly, Sanofi's October 2024 press release noted Enjaymo sales for cold agglutinin disease reached €28 million in Q3 2024, an 81.3% rise, driven by new patient initiations.

Favorable regulatory policies for orphan drugs serve as a crucial driver for innovation, providing market exclusivity and accelerated review processes that effectively reduce barriers to entry. These incentives significantly lessen the financial risks associated with research and development for rare diseases, thereby motivating companies to prioritize niche hematological pipelines despite smaller patient cohorts. The positive influence of this supportive regulatory landscape is clearly demonstrated by recent approval patterns; in 2024, 52% of the 50 novel drugs approved by the FDA received orphan drug designation, as reported by the Regulatory Affairs Professionals Society in January 2025. This sustained policy backing guarantees a continuous introduction of new treatments for acquired orphan blood disorders, underscoring the sector's enduring commercial potential.

Market Challenge

A significant barrier to the expansion of the Global Acquired Orphan Blood Diseases Therapeutics Market is the substantial cost of drug development, which necessitates high pricing strategies. Pharmaceutical firms incur considerable research and development expenses for these specialized treatments, yet the limited patient population compels them to establish high per-patient prices to recoup their investments. This economic model frequently encounters opposition from reimbursement agencies and insurance providers, who often delay or decline coverage for these costly therapies. As a result, even when effective treatments are available, the financial burden often falls on patients or healthcare systems unable to absorb these expenses, consequently limiting market reach and commercial acceptance.

This financial pressure directly restricts patient access, hindering the market's ability to achieve its full revenue potential. Insufficient insurance coverage frameworks further compound the problem, exposing patients to potentially unmanageable costs. For instance, the 'National Organization for Rare Disorders' reported in 2025 that 22 states received 'C' grades, signifying they have only a single policy in place to protect patients from high out-of-pocket prescription drug costs. This lack of extensive reimbursement support creates an unstable climate for manufacturers, as uncertainties surrounding payment structures and patient affordability deter ongoing investment in this critical sector.

Market Trends

A significant trend reshaping the treatment of acquired orphan blood diseases is the transition from intravenous to subcutaneous and oral drug formulations, which enhances patient independence and alleviates the logistical challenges of chronic care. Manufacturers are increasingly adopting self-administered delivery systems over traditional infusion-dependent biologics to improve long-term patient adherence and reduce the need for hospital resources. This shift is particularly noticeable with novel C5 inhibitors, which are developed to allow for manageable home-based regimens instead of frequent clinical visits. Illustrating this regulatory progress, Roche announced in August 2024 the European Commission's approval of PiaSky as the first monthly subcutaneous treatment for paroxysmal nocturnal hemoglobinuria, a breakthrough enabling patient self-administration and substantially lessening the treatment burden compared to standard intravenous therapies.

Simultaneously, the emergence of nanobody-based therapeutics for acquired thrombotic disorders is establishing a new benchmark for treating acute conditions such as acquired thrombotic thrombocytopenic purpura (aTTP). These unique single-domain antibody fragments provide enhanced stability and faster tissue penetration compared to traditional monoclonal antibodies, enabling precise inhibition of disease mechanisms like von Willebrand factor-mediated platelet aggregation. The increasing acceptance of these specialized agents underscores their vital role in managing critical hematologic episodes where a rapid therapeutic effect is crucial for patient survival. Confirming the commercial growth of this drug class, Sanofi reported in October 2024 that Cablivi (caplacizumab) achieved €63 million in sales during Q3, representing a 12.5% increase driven by continued patient expansion in the United States.

Key Market Players

• Alexion Pharmaceuticals, Inc.
• Amgen, Inc.
• Celgene Corporation
• Eli Lilly and Company
• Sanofi S.A.
• GlaxoSmithKline plc,
• Cyclacel Pharmaceuticals, Inc.
• Onconova Therapeutics, Inc.
• Incyte Corporation,
• CTI BioPharma Corp

Report Scope

In this report, the Global Acquired Orphan Blood Diseases Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acquired Orphan Blood Diseases Therapeutics Market, By Therapy

• Recombinant Factor
• Immunoglobulin Infusion Therapy
• Activated Prothrombin Complex Concentrate
• Thrombopoietin Receptor Agonists
• Others

Acquired Orphan Blood Diseases Therapeutics Market, By Disease Indication

• Acquired Agranulocytosis
• Acquired Hemophilia
• Acquired Von Willebrand Syndrome
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Myelodysplastic Syndrome
• Others

Acquired Orphan Blood Diseases Therapeutics Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Acquired Orphan Blood Diseases Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acquired Orphan Blood Diseases Therapeutics Market.

Available Customizations:

Global Acquired Orphan Blood Diseases Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Recombinant Factor, Immunoglobulin Infusion Therapy, Activated Prothrombin Complex Concentrate, Thrombopoietin Receptor Agonists, Others)
  • 5.2.2. By Disease Indication (Acquired Agranulocytosis, Acquired Hemophilia, Acquired Von Willebrand Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Disease Indication
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By Distribution Channel

7. Europe Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Disease Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Disease Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Disease Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By Distribution Channel

10. South America Acquired Orphan Blood Diseases Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Disease Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Acquired Orphan Blood Diseases Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Acquired Orphan Blood Diseases Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Alexion Pharmaceuticals, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Amgen, Inc.
• 15.3. Celgene Corporation
• 15.4. Eli Lilly and Company
• 15.5. Sanofi S.A.
• 15.6. GlaxoSmithKline plc,
• 15.7. Cyclacel Pharmaceuticals, Inc.
• 15.8. Onconova Therapeutics, Inc.
• 15.9. Incyte Corporation,
• 15.10. CTI BioPharma Corp

16. Strategic Recommendations

17. About Us & Disclaimer